Levonorgestrel 52 mg intrauterine system (Levosert®)/Liletta®) in contraception: a profile of its use

[1]  Burak Sezgin,et al.  Vascular effect of levonorgestrel intrauterine system on heavy menstrual bleeding: is it associated with hemodynamic changes in uterine, radial, and spiral arteries? , 2020, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[2]  Magdalena Bofill Rodriguez,et al.  Progestogen-releasing intrauterine systems for heavy menstrual bleeding. , 2020, The Cochrane database of systematic reviews.

[3]  D. Hubacher,et al.  Menstrual Bleeding and Spotting With the Levonorgestrel Intrauterine System (52 mg) During the First-Year Post-Insertion: A Systematic Review and Meta-analysis , 2020 .

[4]  D. Hubacher,et al.  Menstrual bleeding and spotting with the Levonorgestrel Intrauterine System (52 mg) during the first-year post-insertion: a systematic review and meta-analysis. , 2020, American journal of obstetrics and gynecology.

[5]  M. Creinin,et al.  Bleeding changes after levonorgestrel 52mg intrauterine system insertion for contraception in women with self-reported heavy menstrual bleeding. , 2019, American journal of obstetrics and gynecology.

[6]  C. Westhoff,et al.  Six-Year Contraceptive Efficacy and Continued Safety of a Levonorgestrel 52mg Intrauterine System. , 2019, Contraception.

[7]  R. Ferriani,et al.  Effect of the levonorgestrel‐releasing intrauterine system on cardiovascular risk markers among women with thrombophilia or previous venous thromboembolism , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[8]  H. Nabil,et al.  The effect of early vs. delayed postpartum insertion of the LNG-IUS on breastfeeding continuation: a systematic review and meta-analysis of randomised controlled trials , 2019, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[9]  G. Stuart,et al.  Pre-removal plasma levonorgestrel level and return ot fertility after levonorgestrel 52 mg intrauterine system discontinuation , 2019, Fertility and Sterility.

[10]  M. Creinin,et al.  Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. , 2019, Contraception.

[11]  M. Creinin,et al.  Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System , 2018, Obstetrics and gynecology.

[12]  G. Stuart,et al.  Bleeding patterns do not differ between nulliparous and parous women using a levonorgestrel 52 mg intrauterine system , 2018, Fertility and Sterility.

[13]  B. Carr,et al.  Return of fertility in nulliparous and parous women after levonorgestrel 52 mg intrauterine system discontinuation , 2018, Fertility and Sterility.

[14]  B. Carr,et al.  Plasma levonorgestrel levels in non-obese and obese women using a levonorgestrel 52 mg intrauterine system for up to 7 years , 2018, Fertility and Sterility.

[15]  P. Blumenthal,et al.  Bleeding patterns for the Liletta® levonorgestrel 52 mg intrauterine system , 2018, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[16]  I. Cristóbal,et al.  Use of the levonorgestrel-releasing intrauterine device in Spain , 2018 .

[17]  G. Stuart,et al.  Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use. , 2018, Contraception.

[18]  K. Heinemann,et al.  Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study , 2017, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[19]  O. Heikinheimo,et al.  Fast-track vs. delayed insertion of the levonorgestrel-releasing intrauterine system after early medical abortion - a randomized trial. , 2017, Contraception.

[20]  J. Sanders,et al.  One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception. , 2017, Contraception.

[21]  J. Peipert,et al.  Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use. , 2016, Contraception.

[22]  M. Creinin,et al.  A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement. , 2016, American journal of obstetrics and gynecology.

[23]  J. Gobburu,et al.  Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system. , 2016, Contraception.

[24]  J. Sanders,et al.  Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study. , 2016, Contraception.

[25]  I. Cristóbal,et al.  One year quality of life measured with SEC-QoL in levonorgestrel 52 mg IUS users. , 2016, Contraception.

[26]  C. Westhoff,et al.  Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. , 2015, Contraception.

[27]  J. Foidart,et al.  Impact of a new levonorgestrel intrauterine system, Levosert®, on heavy menstrual bleeding: results of a one-year randomised controlled trial , 2014, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[28]  Hajime Tanaka.  Thermodynamic anomaly and polyamorphism of water , 2000 .